Intended for healthcare professionals

Letters Response: Tom MacDonald

Tom MacDonald replies to Marisa de Andrade

BMJ 2009; 339 doi: (Published 21 October 2009) Cite this as: BMJ 2009;339:b4281
  1. Tom MacDonald, professor of clinical pharmacology1
  1. 1Ninewells Hospital and Medical School, University of Dundee, Dundee DD1 9SY
  1. tom{at}

    Thank you for allowing me to respond to Ms Andrade’s article about the Standard Care versus Celecoxib Outcome Trial (SCOT).1

    SCOT was designed by me with Professor C J Hawkey (Nottingham University) and Professor Ian Ford (Glasgow University). The protocol is the property of Dundee University (the study sponsor) and was formally approved by the European Medicines Evaluation Agency (EMEA), as well as other regulatory bodies. The aim of the study is to assess the long term drug safety of non-steroidal anti-inflammatory drugs (NSAIDs) and is funded by Pfizer USA. In general the pharmaceutical industry does not see such safety studies as attractive commercially, which is why SCOT is led by an independent investigator (me) and …

    View Full Text

    Log in

    Log in through your institution


    * For online subscription